Introduction
Successful treatment of STEMI requires early diagnosis and urgent neutralization of lesion through antithrombotic therapy and mechanical revascularization. Modern antithrombotic treatment in conjunction with primary percutaneous coronary intervention (pPCI) has reduced morbidity and mortality in STEMI patients [2] . Nevertheless, effective treatment strategies may be associated with bleeding complications (Fig. 1 ). Depending on the study, the registry and the data source used, 3-14% of STEMI patients experience bleeding during the year following pPCI.
Bleeding in STEMI patients signifi cantly prolongs intensive care unit stay and increases mortality [3] . According to the Thrombolysis In Myocardial Infarction (TIMI) bleeding criteria, TIMI major bleeding increases mortality 5 times and TIMI minor bleeding with transfusion increases the risks 2-3 times [4] .
The effi cacy, but also safety of antithrombotic drugs is crucial because today we use more potent ant iplatelet agents and invasive strategies are now used to treat older patients with comorbidities as well as patients with higher risks of bleeding. Current drug therapy in STEMI patients is based on evidence both from clinical trials in ACS with ST segment elevation and ACS without ST segment elevation or stable coronary artery disease (CAD), because many etiological and pathophysiological factors are similar. Therefore, in the part focused on antithrombotic drugs we discuss the results of trials across a broad spectrum of CAD (not only STEMI). In addition, we comment on experiences and trials from neurology and gastroenterology because these specialties have experience with the management of intracranial or gastrointestinal bleeding complications in patients on antithrombotic therapy. In summary, this review article focuses on current antithrombotic drugs, bleeding risks and complications in STEMI patients.
Pathogenesis of thrombi in STEMI
STEMI represents the most lethal form of acute coronary syndrome (ACS), in which a completely occlusive thrombus results in total cessation of coronary blood fl ow in the region of the infarct related artery and is associated with ST segment elevation on an electrocardiogram (ECG). The majority of myocardial infarctions (MIs) occur in patients with atherosclerotic stenosis associated with superimposed luminal thrombi. Arbustini et al. found coronary thrombi in 98% of patients dying from a clinically documented acute MI, and of those thrombi, 75% were caused by plaque rupture and 25% by plaque erosion [5] .
Plaque rupture or erosion facilitates the interaction between inner plaque components and circulating blood. Tissue factor (TF) is a potent platelet activator and coagulation trigger. Recent research has provided a very detailed picture of the biochemical components and pathways involved in platelet activation.
At the site of a vascular lesion, circulating von Willebrand factor (vWF) binds to exposed collagen within the lesion, which subsequently binds to the glycoprotein IB/IX receptor on the membranes of platelets that are in the immediate vicinity, vWF is secreted from storage organelles in platelets and/or endothelial cells. Interaction of GP (glycoprotein) IB/ IX -vWF is enough to promote binding of platelets to the subendothelium resulting in rapid accumulation of platelets in the site of lesion. GP VI binding to matrix collagen has slower binding kinetics, but when initiated, it promotes firm adhesion of platelet to the vessel surface.
Exposed matrix within a vessel wall and thrombin generated by activation of the coagulation cascade, as well as epinephrine and adenosine diphosphate are powerful platelet agonists. Each agonist stimulates the discharge of calcium and promotes the subsequent release of the platelet's granular content.
Adenosine diphosphate (ADP) released from platelet dense-granules as well as injured cells binds to the P2Y 12 receptors and then induces activation of the GP IIb/IIIa receptor and platelet aggregation. P2Y 12 plays a central role in amplifi cation and stabilization of ADP-induced platelet aggregation.
Cyclooxygenase 1 (COX-1) is the key enzyme in prostaglandine biosynthesis. It converts free arachidonic acid, released from platelet membranes, to thromboxane A (TXA).
TXA further promotes platelet aggregation and is a potent vasoconstrictor. The initial recognition of a damaged vessel wall by platelets involves adhesion, activation and aggregation.
After the initial layer of platelets has spread over the lesion, additional platelets aggregate to form a secondary and tertiary layer of platelets (connection IIb/IIIa receptor-fi brin-IIb/IIIa receptor) and eventually form a white thrombus. In the fi nal step there is recruitment of other cells, e.g. erythrocytes, neutrophils, monocytes, etc. [6] . the platelet (7-10 days). The restoration of normal platelet function, after aspirin administration, occurs only with the production of new platelets. One seventh of circulating platelets are renewed every 24 h; therefore, up to 30% of circulating platelets may show normal TXA 2 production after aspirin discontinuation for 48 h. Low dose aspirin does not affect the action of endothelial cell COX-1 and therefore does not reduce the production of PGI 2 , which has many benefi cial effects including potent antiplatelet effects.
A meta-analysis of 6 randomized trials (2427 patients with a history of myocardial infarction and 1757 patients with a history of transitory ischemic attack or stroke) showed that aspirin substantially reduces all-cause mortality by approximately 18% and nonfatal vascular events by 30% [8] . The optimal dose for effi cacy and safety remains debatable. The results of CURRENT-OASIS 7 trial showed that in patients with ACS (25,086 patients studied, 29% STEMI and 71% non-STEMI or unstable angina pectoris), there was no signifi cant difference after 30 days with regard to the primary outcome (cardiovascular death, MI, stroke) or major bleeding between the higher (300 mg daily) and lower (100 mg daily) dose aspirin groups. This fi nding was similar in the higher dose and lower dose clopidogrel groups [9] .
Antithrombotic drugs

Classifi cation of used antiplatelet agents (Fig. 2)
1. Aspirin blocks cyclo-oxygenase 1 (COX-1).
Platelet P2Y 12 blockers inhibit ADP receptors
ticlopidine, clopidogrel, prasugrel (irreversible inhibitors) -cangrelor and ticagrelor (reversible inhibitors). 3. Glycoprotein IIb/IIIa inhibitors block bridging of platelets by fi brinogen -abciximab, eptifi batide, tirofi ban. 4. Thrombin receptor antagonist PAR (proteaseactivated receptor) -vorapaxar, atopaxar (currently tested in clinical trials). The ESC guidelines for STEMI 2012 recommend aspirin + one of the newer P2Y 12 blockers (prasugrel or ticagrelor) preferred over clopidogrel [7] .
Aspirin (acetylsalicylic acid)
Complete inhibition of platelet aggregation using aspirin usually requires a dosage of about 75 mg/day. It results in an inactive COX-1 enzyme for the remaining lifespan of An analysis of an Italian trial (189,425 individuals from the general population taking low dose aspirin) by Berardis and colleagues showed the overall rate of major bleeding events per 1000 persons/year was 5.58 for aspirin users compared with 3.60 for non-aspirin users (incidence rate ratio 1.55 [95% CI, 1.48-1.63]) [10] .
Continuing usage of low-dose aspirin after endoscopic treatment of a bleeding peptic ulcer (in patients with cardiovascular disease on aspirin) raises the risk of additional bleeding but may also reduce mortality rates, according to a report from Sung et al. Seventy-fi ve patients with peptic ulcer bleeding were assigned to receive aspirin (80 mg/day) and 75 patients received a placebo for 8 weeks after endoscopic therapy. All subjects received intravenous pantoprazole (80 mg bolus, 8 mg/h for 72 h, followed by oral pantoprazole [40 mg/day] until the end of the study). The rate of recurrent ulcer bleeding at 30 days was nearly twice as high in the aspirin group compared to the placebo group: 10.3% vs. 5.4% (p = 0.25). However, the all-cause mortality rate at 8 weeks was much lower in the aspirin group: 1.3% vs. 12.9% (p < 0.01) due to the reduction of cardiovascular and cerebrovascular complications [11] .
P2Y 12 receptor antagonists
The important role of the P2Y 12 receptor in platelet activation and thrombus formation has made it a crucial target in the management and prevention of arterial thrombosis.
Clopidogrel is an intestinally absorbed prodrug that is converted to its active metabolite in the liver by cytochrome P-450. It is estimated that approximately one third of clopidogrel-treated patients exhibit a diminished platelet response to clopidogrel. The results of the CURRENT--OASIS 7 trial in ACS patients showed a non-signifi cant benefi t of 150 mg/day over 75 mg/day clopidogrel in the whole population. However, a subgroup analysis showed a benefi t from increased clopidogrel dose during the fi rst week in ACS patients treated with PCI [12] .
Is clopidogrel safer than aspirin with the respect of bleeding rate? The results of CAPRIE study (19, 185 patients with atherosclerotic vascular disease that manifested either as a recent MI, ischemic stroke or symptomatic peripheral arterial disease) did not show signifi cant differences in major bleeding between aspirin (300 mg/day) and clopidogrel (75 mg/day) group [13] .
The MATCH trial (8600 patients with recent ischemic stroke or transient ischemic attack and at least one vascular risk factor) documented that the use of clopidogrel 75 mg + aspirin 75 mg caused more life-threatening bleeding than clopidogrel alone. At 18 months dual antiplatelet (DAPT) therapy increased life-threatening bleedings (2.6% vs. 1.3%); absolute risk increase 1.3 (95% CI 0.6-1.9). Major bleeding was also increased in the group receiving aspirin and clopidogrel but no difference was recorded in mortality [14] .
The utility of tailored treatment with clopidogrel based on platelet function tests is now widely discussed.
The GRAVITAS study (2800 patients with ACS without ST segment elevation undergoing PCI and drug-eluting stent implantation) showed that although doubling the clopidogrel maintenance dose in poor responders may improve the measured response, it does not necessarily improve outcomes [15] . In addition, the large clinical ARCTIC trial (2440 patients without STEMI, who were scheduled to undergo PCI with drug-eluting stents) did not confi rm any signifi cant improvements in clinical outcomes with platelet function monitoring and treatment adjustment for coronary stenting, compared with standard antiplatelet therapy without monitoring [16] . Genetic testing before starting clopidogrel therapy, in high-risk patients, and platelet function testing in those who suffer adverse events may facilitate the monitoring of clopidogrel treatment.
The possible interaction between clopidogrel and proton pump inhibitors is mentioned below (section on prevention of bleeding).
The next two drugs, prasugrel and ticagrelor are faster in action, more potent and more predictable than clopidogrel [17] and thus should be the preferred in combination with aspirin if not contraindicated.
Prasugrel is a pro-drug, its active metabolite appears in the circulation within 15 min of receiving a 60 mg loading dose [18] . In patients with documented CVD undergoing cardiac catheterization with PCI for angina pectoris, a 60 mg loading dose of prasugrel resulted in greater platelet inhibition than a 600 mg loading dose of clopidogrel [19] . Furthermore, a prasugrel maintenance dose of 10 mg/day results in more potent and consistent inhibition of platelet activation than a clopidogrel maintenance dose of 75 or 150 mg/day.
In the TRITON-TIMI 38 study, reduced rates of ischemic events (especially in diabetic or STEMI patients), including stent thrombosis in ACS patient undergoing PCI, were seen in prasugrel treated patients compared to the clopidogrel group. On the other hand, an increased rate of serious bleeding and fatal bleeding was also observed. Overall mortality did not differ between the two treatment groups [20] .
In a subgroup of STEMI patients prasugrel and clopidogrel had similar safety profi les with respect to bleeding. Following 15 months of treatment, the rate of TIMI major and minor non-CABG bleeding in prasugrel and clopidogrel treated patients were comparable (5.1% vs. 4.7%, p = 0.65). Furthermore, prasugrel, compared with clopidogrel, did not signifi cantly increase the rate of life-threatening bleeding (1.3 vs. 1.1%, respectively) [21] .
The recommendation for discontinuing of prasugrel prior to cardiac surgery is 7 days. Prasugrel should not be administered to patients with a prior history of strokes or transient ischemic attacks. In patients aged > 75 years, prasugrel is generally not recommended because of the increased risk of fatal and intracranial bleeding and the uncertain benefi t; additionally, consideration should be given to lowering the maintenance dose to 5 mg in patients weighing < 60 kg.
In the TRILOGY trial, prasugrel failed to show a reduction in major cardiovascular events compared with clopidogrel in patients with acute coronary syndrome (ACS) with non-ST segment elevation and who were managed medically, i.e. without revascularization [22] . Interestingly, there were no differences (at the 30 months follow up) between the prasugrel and clopidogrel group in patients < 75 years and the overall population relative to rates of global use of strategies to open occluded coro-nary arteries (GUSTO); severe/life-threatening and TIMI major bleeding; and fatal and intracranial bleeding. A lower dose of prasugrel (5 mg) was used in those aged ≥ 75 years and in those weighing < 60 kg and appeared to be safe.
Ticagrelor is a nucleoside analog absorbed quickly from the gut and reaches peak concentration after 90 min. The drug plus its main metabolite are both pharmacologically active and are mainly excreted via bile and feces.
In the PLATO study (ticagrelor vs. clopidogrel), in patients with ACS, 7544 patients had STEMI. In these patients, a 13% reduction in the primary endpoint (incidence of MI, stroke or vascular death) was observed. There was no signifi cant difference between the two trial arms with respect to any category of bleeding (major, minor, life-threatening, CABG or non-CABG related), except for the combination of no-procedure-related major and minor bleeding, which was more common with ticagrelor than with clopidogrel (5.1% vs. 3.7%) [23] .
Contraindications for ticagrelor are a history of intracranial bleeding, as well as reduced liver function. Ticagrelor should be indicated with caution in patients with bradycardia or severe chronic obstructive pulmonary disease (COPD).
Cangrelor is parenteral P2Y 12 inhibitor with very short half-life; restoration of platelet function is observed within 60 min of drug discontinuation. This pharmacokinetic characteristic might be advantageous relative to urgent surgery. However, in the CHAMPION PCI study, cangrelor failed to show a benefi t over clopidogrel [24, 25] .
Glycoprotein IIb/IIIa inhibitors
Abciximab, the most widely used agent from the glycoprotein (GP) IIb/IIIa inhibitors, is indicated as an addition to dual antiplatelet drug therapy (DAPT) in pPCI for the prevention of cardiac ischemic complications in patient with angiographic evidence of a large thrombus, TIMI fl ow 0-1, or other thrombotic complications, e.g. distal embolism [7] .
The onset of abciximab effect (bolus dose) is less than 10 min. Its modifi cation of platelet function lasts for up to 48 h after the infusion has been terminated, and low levels of GP IIb/IIIa receptor blockade are present for up to 15 days after the infusion is terminated.
In the STEMI-abciximab meta-analysis [26] , major bleeding complications were higher with abciximab than placebo (4.7% vs. 4.1%; OR 1.16, p = 0.36), intracranial bleeding was the same.
Gu et al. studied 534 patients with STEMI and compared intracoronary (i.c.) abciximab to intravenous (i.v.) administration [27] . They found no difference relative to the combined endpoint of death, reinfarction or congestive heart failure. However, myocardial reperfusion, as assessed using myocardial blush and infarct size, were improved in the intracoronary group. Infarct size was similarly reduced, by about 30%, when measured using either creatine kinase-MB or cardiac troponin T. But cardiac enzyme was obtained in only 46% of patients. The incidence of in hospital major and minor bleeding was low and similar in both groups.
In meta-analysis from 8 randomized trials with 3259 patients by De Luca et al. [28] it was documented that i.c. administration of abciximab is associated with signifi cant benefi ts in myocardial perfusion but not in clinical outcome at the short-term follow-up compared to i.v. abciximab administration, without any excess in major bleeding in STEMI patients undergoing pPCI.
The AIDA STEMI study [29] with 2065 patients compared i.c. vs. i.v. abciximab and found a similar rate for the primary composite clinical endpoint -death/MI/heart failure at 90 days (7.0% vs. 7.6%; OR [95% CI] 0.91 [0.64-1.28], p = 0.58). For death, the results showed non-signifi cant difference (4.5% vs. 3.6%; OR 1.24 [0.78-1.97], p = 0.36). Reinfarction also did not differ between the treatment groups (1.8% vs. 1.8%; OR 1.0 [0.51-1.96], p = 0.99), whereas less patients in the intracoronary group had new congestive heart failure (2.4% vs. 4.1%; OR 0.57 [0.33-0.97], p = 0.04). Bleeding was not signifi cantly different between i.v. vs. i.c. groups.
To date, there is no experience using combinations of abciximab and any of the newer antiplatelet agents, such as prasugrel or ticagrelor; however, such a coadministration could increase the risk of bleeding and therefore should be used with caution.
Eptifi batide is a peptide that reversibly binds to GP IIb/ IIIa receptors. It has a very short half-life; as an example, four hours after cessation of infusion, patients have safely undergone CABG.
The large SCAAR registry (11,000 STEMI patients) suggests that eptifi batide is not inferior to abciximab in STEMI patients undergoing primary PCI with respect to the occurrence of death or MI at the 1 year follow up; this supports the use of either drug in clinical practice [30] .
In patients after recent primary PCI with stent implantation, who require cessation of P2Y 12 before surgery, bridging with GP IIb/IIIa inhibitors appears effective in preventing adverse cardiac events; however, it may be associated with bleeding in patients undergoing cardiac surgery [31] .
At the 3-year follow-up of the HORIZONS-AMI trial, eptifi batide and abciximab had comparable bleeding risks and clinical effi cacy in patients after primary PCI [32] .
Anticoagulants
In STEMI patients, 3 The most frequent used anticoagulant in practice today is unfractionated heparin (UFH). It is a drug with long history, much experience and has an effective antidote (protamine). Bivalirudin is a specifi c and reversible direct thrombin inhibitor. In the HORIZONS-AMI study, the superiority of bivalirudin was demonstrated over a combination of UFH + abciximab. This study reported reduction in all cause and cardiovascular (CV) mortality at 30 days up to 3 years, and the risk of bleeding was also reduced [33] .
In a retrospective study of 900 US patients, bivalirudin was compared to heparin (without GP IIb/IIIa inhibitors). The results confi rmed a similar safety and effi cacy profi le for both drugs [34] . Enoxaparin is recommended as an alternative to UFH or bivalirudin. Comparison of enoxaparin vs. UFH in the ATOLL study showed that enoxaparin reduced the combined ischemic endpoint of death, reinfarction or urgent revascularization (8.5% vs. 5.1%, p = 0.04). The incidence of major bleeding did not differ between groups (5% vs. 5%; p = 0.79) [35] .
Bleeding scores and predictors
Bleeding events are important endpoints for the assessment of drugs and safety profi les during randomized trials. There are many data from several trials relative to bleeding, but unfortunately, to date, there has been a lot of non-homogeneity regarding the defi nition of bleeding and its categorization (i.e. minor, moderate, major, life--threatening, severe, serious, with need of transfusion, etc.) and many different classifi cations are used, e.g. TIMI [36] (Table 1) , GUSTO [37] , STEEPLE, GRACE, PLATO etc. Therefore, it is diffi cult to compare results between trials ( Fig. 3) [38] . In 2010, academic research on bleeding and drug administration developed new a universal bleeding classifi cation for cardiovascular clinical trials, called the BARC classifi cation [39] , which consists of 5 types of bleeding ( Table 2) .
Rates of bleeding complications have been steadily dropping after elective percutaneous coronary interventions according to registry data published in May 2012 [40] . However, the decrease was not seen in STEMI patients.
Based on the results from many studies, several important predictors of bleeding are known (Fig. 4) . The most common is age; other strong predictors are shock, use of anticoagulant treatment and/or NSAIDs, prior history of bleeding, renal failure, comorbidities (sepsis and mechanical ventilation and diabetes mellitus). Other predictive factors include: low body weight, obesity, anemia and female gender. Moreover, antithrombotic treatment strategies (e.g. the use of GP IIb/IIIa inhibitors) also play an important role [41] .
The relationship between bleeding and mortality is both direct and indirect. Intracranial and gastrointestinal hemorrhages are well recognized as potentially fatal events. However, consequences of bleeding may have other detrimental effects:
(1) Interactions between activated platelets and clotting cascade produce a rapid hemostatic response at site of vascular injury and defi ciency of an antithrombotic protective mechanism. (2) Further, procoagulation factor i.e., increased erythropoietin synthesis in response to anemia caused by bleeding. Systemic prothrombotic states might last beyond the acute phase, by causing platelet activation and inducing plasminogen activator inhibitor-1 synthesis [42] . (3) In the presence of severe bleeding antithrombotic medication is almost always withdrawn or reduced at least temporarily. (4) Finally, the use of transfusions has prothrombotic effects and increases mortality in STEMI patients [43] .
A meta-analysis of the REPLACE-2, ACUITY and HORI-ZONS-AMI trials performed by Mehran et al. showed that non-CABG related bleeding within 30 days was strongly associated with an increased risk of 1 year mortality in patients undergoing PCI for all indications [4] . 
Non-modifi able Modifi able 5 Source of bleeding after STEMI
Post-STEMI bleeding is divided into access site (40-50%) and non-access site bleeding (50-60%). As mentioned earlier, the ratio between access site and non-access site bleeding found in different studies varies depending on the bleeding classifi cation used. Several factors appear to infl uence the reported rate of bleeding complications in clinical trials, including: (1) population inclusion/exclusion criteria, (2) rate and type of invasive procedures, (3) bleeding defi nition, and (4) antithrombotic agents used [44] .
Non-access site bleeding
The gastrointestinal (GI) tract is the most common non--access site bleeding (1 year incidence 0.7-3.5%). The greatest risk is previous GI bleeding. The majority of bleeding is in upper GI tract (ulcer or erosion of stomach, duodenum and esophagus). Prevention and treatment are discussed below.
Intracranial bleeding (0.1-0.4%) is the most serious location of bleeding. In the thrombolytic era, the incidence of intracranial bleeding between streptokinase vs. alteplase treated patients was 0.5% vs. 0.7%, p = 0.03 (GUSTO trial) [37] .
In the era of primary PCI, the incidence of intracranial bleeding has dropped below 0.4% per 1 year for STEMI. In intracranial bleeding, immediate withdrawal and antagonization of the antithrombotic drug is mandatory and close cooperation with the neurosurgeon is needed.
Urogenital bleeding (0.5-1.5%) is usually temporary and not associated with the need for a blood transfusion or surgical intervention.
Occasionally one can see bleeding in respiratory tract or signifi cant drops of hemoglobin without a clinically proven bleeding site.
Retroperitoneal bleeding (which can be diffi cult to diagnose) is pure non-access bleeding when other than femoral approach for coronary catheterization and intervention is used.
Access site bleeding
Puncture site for the primary PCI is the most frequent source of bleeding. These complications in clinical practice include large hematomas in the groin, arterio-venous (AV) fi stulas, aneurysms and pseudoaneurysms of artery or retroperitoneal bleeding. Fortunately, these complications may be substantially reduced when the radial approach is used in an experienced center. Although the radial artery is superfi cial and hemostasis can be achieved easily, access site bleeding can occur that, if left unchecked, can lead to forearm hematoma and rarely, to compartment syndrome [45] .
In case of femoral approach the use of closure device may be considered. However, studies have not shown a signifi cant benefi t in terms of a reduction in access site complications, including bleeding risks. The main advantage of closure devices is that they are more comfortable for patients.
Jolly et al. in 2009 documented the benefi t of the radial vs. femoral approach in the fi rst large meta-analysis on the subject [46] . They reviewed 13 studies and 1958 STEMI patients who had been randomized to trans-radial approach (TRA) vs. trans-femoral approach (TFA). This analysis showed a remarkable and highly signifi cant 73% reduction of major bleeding complications in the TRA arm. Interestingly, this dramatic reduction of major bleeding complications was also associated with a trend toward fewer deaths, myocardial infarctions, and strokes (OR 0.71; 95% CI, 0.4 -1.01; p = 0.06) in TRA compared to the TFA group.
The benefi t of TRA over TFA (both lower morbidity and cardiac mortality) was subsequently documented in a meta-analysis by Mamas et al. [47] . The researchers chose 9 studies from 2003 to 2011 and included a total of 2977 STEMI patients. Within the studies, 1460 patients underwent transradial PCI and 1517 patients had transfemoral PCI. Patients with the TRA had a 45% relative reduction in major bleeding; additionally, a 70% reduction in access site complications and 48% relative reduction in mortality were found.
The next meta-analysis, comparing the radial and femoral approach in primary PCI for STEMI was published by Joyal et al. [48] . The study included 10 trials involving 3347 patients. The inclusion criteria were a randomized study design, a patient with documented STEMI undergoing primary PCI, a control group undergoing femoral access, and the type of clinical outcome (death, major bleeding, vascular complications, or hematoma), and procedure time. The radial approach was associated with improved survival (OR 0.53; 95% CI, 0.33-0.84, p = 0.93) and reduced vascular complications/hematoma (OR 0.35; 95% CI, 0.24-0.53, p = 0.66). A non-signifi cant trend was found toward reduced major bleeding using the radial approach (OR 0.63; 95% CI, 0.35-1.12, p = 0.79) The RIVAL trial randomized patients with ACS into intervention by femoral approach vs. the radial approach. In the STEMI subgroup (1958 patients), the authors found a statistically signifi cant reduction in primary endpoint (death, MI, stroke and non-CABG bleeding) and non-signifi cant difference in non-CABG major bleeding (according to OASIS bleeding classifi cation) [49] .
The RIFLE STEACS trial (Radial Versus Femoral Randomized Investigation in ST-Elevation Acute Coronary Syndrome) was a multicenter, randomized, parallel-group study with 1001 acute STEMI patients undergoing primary/rescue percutaneous coronary intervention. Patients were randomized into the radial (n = 500) or femoral (n = 501) approach between 2009 and 2011 [50] . Romagnoli et al. reported a signifi cant reduction in primary endpoint, i.e. 30 day rate of net adverse clinical events (NACE = composite of cardiac death, stroke, myocardial infarction, target lesion revascularization, and bleeding at 30 days): 13.6% in the radial access group vs. 21.0% in the femoral (p = 0.003). Radial access was associated with signifi cantly lower cardiac mortality (5.2% vs. 9.2%, p = 0.02) and bleeding (7.8% vs. 12.2%, p = 0.026). Non-access site bleeding did not differ between groups, but signifi cant reduction (62%) of access site bleeding was documented in the radial access group.
Based on the results of the RIVAL-STEMI substudy and the RIFLE STEACS study, the ESC 2012 guidelines for STE-MI recommend the preference of radial access over femoral access for primary PCI (level of recommendation IIaB), if the procedure is performed by experienced radial operator.
Prevention of bleeding
The predictors of bleeding are known (see above), but a specifi c risk score for STEMI patients regarding a rapid estimation of bleeding risk has not yet been developed. In 2009 the CRUSADE Bleeding Score, for prediction of in hospital bleeding, was created for NSTEMI patients [51] . The preference of radial access and/or smaller access sheath size for coronary catheterization in experienced centers has been already mentioned. Care of the puncture site after the intervention is also of importance. For hemostasis, many radial compression devices exist, for example: Hemostop (Zoom Co. Medic), RadiStop (Radi Medical Systems), RadStat (Merit Medical Systems), TR Band (Terumo) [52] .
Based on an evaluation of both thrombotic and bleeding risk, tailored treatment strategies should be used for every patient. One should take into account the age and weight of the patient, renal function, etc. Moreover, the proper dose and dose adjustment of antithrombotic drugs is needed and one should avoid combinations of antithrombotic drugs without proven effi cacy and safety. In the current era, this is of the most importance, since both novel antiplatelet drugs (ticagrelor, prasugrel) and anticoagulants (factors Xa inhibitors -rivaroxaban, apixaban and thrombin inhibitors -dabigatran) are administered in the treatment of ACS patients and patients with atrial fi brillation respectively, but their combinations have not been tested in clinical trials yet. One of the most frequent non-access site bleeding complications is bleeding from a gastroduodenal ulcer and/ or erosions. In recent years, possible interactions between proton pump inhibitors (PPI, namely omeprazole) and clopidogrel (possibly resulting in reduced clopidogrel effect) have been discussed. Although laboratory proven, the interaction between clopidogrel and omeprazole has not been shown to increase cardiovascular risks with drug coadministration in patients with ACS, whereas a signifi cant reduction in gastrointestinal bleeding with PPIs use was observed [53] . The retrospective CALIBER study (UK, 2012) included 24,471 patients with ACS. Patients were prescribed clopidogrel and aspirin and 12, 439 (50%) also PPI. The interaction between the PPI and clopidogrel was not clinically important [54] . Therefore, concurrent clopidogrel and PPI use (with the possible preference of pantoprazole) appears safe, but co-prescription is recommended only for patients at risk for gastrointestinal complications.
Novel P2Y 12 blockers (ticagrelor, prasugrel) do not have any interactions with PPI, are more effi cient than clopidogrel, but this also suggests a need for more widespread PPI use during DAPT (or triple antithrombotic therapy). Based on ESC 2012 STEMI guidelines, PPI should be considered for patients with a history of GI bleeding and are appropriate for patients with multiple risk factors, such as advanced age, anticoagulation, steroids, NSAIDs. H2 blockers are insuffi cient in prevention (5 times weaker than PPI for upper GI bleeding prevention).
There are several specifi c patient subgroups for higher risks of bleeding, e.g. patients with renal insuffi ciency or patients undergoing surgery. In addition, diffi cult clinical scenarios can occur when STEMI patients also require long-term anticoagulation, i.e. patient with mechanical valve or atrial fi brillation with CHA 2 DS 2 -VASc score ≥ 1. In these patients, there are both high thrombotic (intracardiac thrombi or stent thrombosis) and bleeding risks, which may be estimated using the HAS-BLED score, it is preferable to implant a bare-metal stent instead of drug-eluting stent unless the latter is absolutely indicated. The second point is the strategy of long-term post-PCI antithrombotic treatment. When anticoagulant treatment is indicated, it cannot be replaced by antiplatelet agents; therefore the dilemma is the type and duration of antiplatelet therapy. Higher HAS-BLED score (≥ 3 points) does not necessarily indicate antithrombotic treatment cessation, but clinicians should be very careful and intensify monitoring for bleeding occurrences.
Current ESC guidelines recommend triple therapy (oral anticoagulant + aspirin + clopidogrel) and the duration of DAPT is based on the type of stent and type of the event (i.e. elective PCI vs. PCI in ACS). It is well known, that this triple therapy is associated with signifi cantly higher bleeding risks. The recently published WOEST trial compared OAC + DAPT (aspirin + clopidogrel) vs. oral anticoagulant + clopidogrel (without aspirin) [55] . Approximately one third of the patient population had ACS. The authors observed signifi cantly higher incidences of bleeding in triple therapy group and interestingly also higher mortality and combined endpoint at 12 months in the triple therapy group (Fig. 5 ). Further and larger studies are clearly needed with this specifi c patient population. At present, triple therapy with oral anticoagulant + aspirin + prasugrel or ticagrelor is not recommended since it might increase the risk of bleeding.
The most frequent reason for P2Y 12 inhibitors and/or aspirin cessation is surgery, bleeding and non-compliance of the patient with treatment. Dual antiplatelet therapy is recommended for 12 months after STEMI events. During this period the patient may require planned or urgent non-cardiac surgical procedures. Antiplatelet therapy maintenance or withdrawal in these scenarios is not based on evidence, but on expert opinion taking into account the bleeding risk of the procedure and time after STEMI. Duration of stent endotelisation is in detail discussed in chapter 7. At this point we will summarize briefl y our local strategy, which is based on the data from literature [56, 57] .
(1) Patients on aspirin monotherapy (usually longer than 12 months after a STEMI event). Prior to surgery, aspirin can be continued without interruption, with the exception of intracranial and selected ophthalmic surgery, where aspirin should be discontinued 7 days prior to surgery. Before the majority of surgical procedures, aspirin should be continued and the P2Y 12 blocker withdrawn 7 days before surgery. In dental procedures, DAPT is maintained. In patients undergoing intracranial and selected ophthalmic surgery, withdrawal of DAPT should be considered (at least the P2Y 12 blocker).
Management of all above mentioned situations require a close multidisciplinary approach (cardiologist, anesthesiologist and surgeon) in the pre-, peri-and postoperative period.
Treatment of bleeding and discontinuation of antiplatelet therapy
The treatment of clinically signifi cant bleeding is primarily based on attempts to control the source of bleeding.
In access site bleeding after pPCI it is necessary to extract the femoral sheath with subsequent careful compression. For severe gastrointestinal bleeding it is an early endoscopic exam and treatment, i.e. PPI in continual i.v. infusion in doses of 8 mg/h for the fi rst 3 days. With respect to a temporary withdrawal of antiplatelet drugs (aspirin or P2Y 12 antagonist or both), the optimal strategy in patients on DAPT and peptic ulcer bleeding remains to be determined and should be tailored to every patient. If there is a suspicion of intracranial bleeding, a CT scan is urgently indicated and after confi rmation of a brain hemorrhage, consultation with neurosurgery is required. If there is urethral bleeding, then the insertion of urethral 3 way catheter is needed.
In life-threatening bleeding, the immediate discontinuation and eventually antagonism of antiplatelet therapy is indicated (antidotes -see Table 3 ) [57] .
Administration of a transfusion and/or platelets must be reserved for only serious bleeding with circulatory instability, because inappropriate transfusion of red cells worsens the prognosis. Premature discontinuation of antiplatelet therapy may be at the cost of increased incidences of cardiovascular mortality and morbidity [58] .
In an Italian study [59] with 1358 patients (STEMI 30%) after PCI + drug-eluting stent (sirolimus-eluting stent 707 patients and paclitaxel-eluting stent 651 patients), early discontinuation of clopidogrel and/or aspirin (in the fi rst month) signifi cantly increased the rate of stent thrombosis (7.6 % vs. 3.4 %, p = 0.038), MACE (28.6 % vs. 13.7 %, p < 0.001) and cardiovascular death (5 % vs. 1.2 %, p < 0.007).
Premature discontinuation of dual antiplatelet treatment is strongly associated with stent thrombosis, which may manifest as STEMI, malignant arrhythmias or even sudden death [60] . Stent thrombosis is a platelet mediated process that occurs through progressive platelet activation and aggregation ultimately leading to thrombus formation. PCI causes endothelial and tunica media damage that heals via neointimal formation. This process usually lasts up to 6-12 weeks with bare-metal stents (BMS) and up to 6-12 months with drug-eluting stents [61] . It seems that time to endothelization will be decreased with the newest generations of DES, either second generation, or DES with bioresorbable polymers and fully bioresorbable stents [62] . Hopefully, the recommended duration of DAPT after STEMI events can be shortened. In December 2013 we expect results from the DAPT STEMI study [63] -a randomized, open label trial of 6 months vs. 12 months with dual antiaggregation therapy (aspirin + prasugrel or ticagrelor) after pPCI + drug-eluting stent. Discontinuation of aspirin increases risk of CV morbidity and mortality in patients with cardiovascular comorbidities. A retrospective trial from Sweden with 118 patients after aspirin discontinuation documented that 44 of 118 patients (37%) either died or developed acute cardiovascular events. It means that patients with cardiovascular comorbidities who stop low-dose aspirin therapy had an almost 7-fold increased risk for death or acute cardiovascular events (hazard ratio, 6.9; 95% confi dence interval, 1.4-34.8) compared to patients continuing this therapy during the fi rst 6 months of the follow-up period. On the contrary, such an association was not observed among patients without cardiovascular comorbidities [64] .
Future
Although prasugrel and ticagrelor act more quickly than clopidogrel, there remains a need for an affective intravenous formulation of a P2Y 12 blocker in patients before surgical intervention, patients with impossible or impaired gut absorption (e.g. after cardiopulmonary resuscitation, cardiogenic shock, mechanical ventilation with deep sedation, etc.). It is also important to have agents that are rapidly reversible in patients awaiting surgical intervention.
New agents (e.g. vorapaxar) are in development. There is also a place for testing new combinations of drugs. The BRAVE-4 study (prasugrel + bivalirudin vs. UFH + clopidogrel) is under way. The question is whether aspirin will remain an indispensable part of antiplatelet therapy in the era of newer, more potent P2Y 12 inhibitors and if novel anticoagulants can be combined with other antiplatelet agents. Recent developments in catheters and closure devices have opened other fi elds regarding improvements in primary PCI results with reduced risks of bleeding.
Last but not least, genetic testing will be probably used more widely in clinical practice as a method of individualizing patient care.
Conclusion
Patients with acute myocardial infarction with ST segment elevation are indicated for combined anticoagulant and dual antiplatelet treatment as soon as possible after establishing the diagnosis with subsequent early primary PCI with stent implantation. Dual antiplatelet therapy is then administered usually for one year. This strategy, which reduces immediate and long-term ischemic risks, carries a higher short-term and long-term risk of bleeding, which is a very important predictor of morbidity and mortality. The preference of radial access in centers experienced with the procedure signifi cantly reduced bleeding complications and improved clinical outcomes in STEMI patients. After individual stratifi cation of thrombotic and bleeding risks one should apply measures to reduce the risk of these complications using effective and safe combinations of antiplatelet and anticoagulant agents while minimizing the risks of bleeding. Similarly, when bleeding occurs, a tailored treatment approach should be applied for each individual patient.
